Last reviewed · How we verify
Placebo for liraglutide
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect.
A placebo contains no active pharmaceutical ingredient and produces no direct pharmacological effect. Used for Control arm in clinical trials for liraglutide (GLP-1 receptor agonist for type 2 diabetes and obesity).
At a glance
| Generic name | Placebo for liraglutide |
|---|---|
| Sponsor | Per-Ola Carlsson |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebo is an inert substance used as a control in clinical trials to establish the efficacy of an active drug by comparison. Any observed effects in placebo groups are attributed to the placebo effect (psychological and contextual factors) rather than direct drug action. Placebos are essential for blinded trial design to isolate the true therapeutic benefit of the active comparator.
Approved indications
- Control arm in clinical trials for liraglutide (GLP-1 receptor agonist for type 2 diabetes and obesity)
Common side effects
Key clinical trials
- The Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in People With Type 1 and Type 2 Diabetes (PHASE2)
- Liraglutide Effects on Epicardial Fat Inflammatory Genes (PHASE4)
- Saxenda: Underlying Mechanisms and Clinical Outcomes (PHASE4)
- Liraglutide in Preventing Delirium in Diabetic Elderly After Cardiac Surgery (PHASE3)
- Use of a GLP-1R Agonist to Treat Opioid Use Disorder (PHASE1, PHASE2)
- Effect of GLP-1 Receptor Agonism After Sleeve Gastrectomy (PHASE3)
- Efficacy of Liraglutide Therapy in Patients With IPAA (PHASE2)
- Research Study Investigating How Well NNC0174-0833 Works in People Suffering From Overweight or Obesity. (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo for liraglutide CI brief — competitive landscape report
- Placebo for liraglutide updates RSS · CI watch RSS
- Per-Ola Carlsson portfolio CI